OTR Acquisition, a blank check company formed by the co-founder of Cyrus Capital and Standard General, raised $100 million by offering 10 million units at $10. The company offered 1.5 million fewer units than anticipated. It originally planned to offer 25...read more
2020’s SPAC mania is showing signs of fatigue. A record-shattering 168 blank check IPOs have raised $57 billion this year, more proceeds than...read more
OTR Acquisition, a blank check company formed by the co-founder of Cyrus Capital and Standard General, lowered the proposed deal size for its upcoming IPO on Monday. The Miami, FL-based company now plans to raise $115 million by offering 11.5 million units...read more
Three drug developers and a medical imaging company went public this past week, joined by eight SPACs. Preclinical protein degradation biotech Kymera Therapeutics (KYMR) upsized and priced above the range to raise $174 million at a $938...read more
Investment veteran's SPAC OTR Acquisition prices further downsized $100 million IPO at $10
OTR Acquisition, a blank check company formed by the co-founder of Cyrus Capital and Standard General, raised $100 million by offering 10 million units at $10. The company offered 1.5 million fewer units than anticipated. It originally planned to offer 25...read more
Blank check investors grow more selective amid SPAC boom
2020’s SPAC mania is showing signs of fatigue. A record-shattering 168 blank check IPOs have raised $57 billion this year, more proceeds than...read more
Investment veteran's SPAC OTR Acquisition decreases deal size by 54% ahead of $115 million IPO
OTR Acquisition, a blank check company formed by the co-founder of Cyrus Capital and Standard General, lowered the proposed deal size for its upcoming IPO on Monday. The Miami, FL-based company now plans to raise $115 million by offering 11.5 million units...read more
US IPO Weekly Recap: Biotechs and SPACs ride the summer wave in a 4 IPO week
Three drug developers and a medical imaging company went public this past week, joined by eight SPACs. Preclinical protein degradation biotech Kymera Therapeutics (KYMR) upsized and priced above the range to raise $174 million at a $938...read more